Denny Xu

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.

Cooley advised the underwriters on Verve Therapeutics’ $306.7 million initial public offering of 16,141,157 shares of common stock. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Verve Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol VERV, is a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene-editing medicines. Partners Brent Siler, Div Gupta and Richard Segal led the Cooley team.

Cooley advised the underwriters on Talaris Therapeutics' $150 million initial public offering of 8,825,000 shares of common stock. Morgan Stanley, SVB Leerink, Evercore Groupand Guggenheim Securitiesacted as joint book-running managers for the offering. Talaris Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol TALS, is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation. Partners Richard Segal, Marc Recht and Div Gupta led the Cooley team.

Cooley advised the underwriters on Werewolf Therapeutics’ $120 million initial public offering of 7,500,000 shares of common stock. Jefferies, SVB Leerink and Evercore Group acted as joint book-running managers. Werewolf Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol HOWL, is an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Partners Brent Siler, Madison Jones and Div Gupta led the Cooley team.

Cooley advised Archer, a leader in the urban air mobility space, on its agreement to combine with special purpose acquisition company Atlas Crest Investment. Estimated to have an implied $3.8 billion pro forma equity value, the combined company will list on the New York Stock Exchange under the symbol “ACHR.” Partners Dave Peinsipp, John McKenna and Al Browne led the Cooley team advising Archer on the transaction, which is expected to close in Q2.